1. J Clin Invest. 2022 Jul 15;132(14):e156290. doi: 10.1172/JCI156290.

Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down 
syndrome leukemia model.

Arkoun B(1)(2)(3), Robert E(3), Boudia F(3), Mazzi S(1), Dufour V(4), Siret 
A(3), Mammasse Y(4), Aid Z(3), Vieira M(1), Imanci A(1), Aglave M(5), Cambot 
M(4), Petermann R(4), Souquere S(6), Rameau P(7), Catelain C(7), Diot R(8), 
Tachdjian G(8), Hermine O(2)(9), Droin N(1)(10), Debili N(1), Plo I(1)(2), 
Malinge S(3)(11), Soler E(2)(12), Raslova H(1), Mercher T(3), Vainchenker 
W(1)(2).

Author information:
(1)INSERM, UMR1287, Gustave Roussy, Université Paris-Saclay, Equipe Labellisée 
Ligue Nationale Contre le Cancer, Villejuif, France.
(2)Laboratory of Excellence GReX, Université de Paris, Paris, France.
(3)INSERM, UMR1170, Gustave Roussy, Université Paris-Saclay, Equipe Labellisée 
Ligue Nationale Contre le Cancer, OPALE Carnot Institute, PEDIAC consortium, 
Villejuif, France.
(4)Institut National de la Transfusion Sanguine (INTS), Paris, France.
(5)Gustave Roussy, Plateforme de Bioinformatique.
(6)Gustave Roussy, Université Paris-Saclay, and.
(7)Gustave Roussy, Plateforme Imagerie et Cytométrie, Université Paris-Saclay, 
UMS AMMICA, INSERM US23, CNRS UMS 3655, Villejuif, France.
(8)Assistance Publique-Hôpitaux de Paris, Service d'Histologie, Embryologie et 
Cytogénétique, Université Paris-Saclay, Hôpital Antoine Béclère, Clamart, 
France.
(9)INSERM U1163/CNRS ERL8254-Laboratory of Cellular and Molecular Mechanisms of 
Hematological Disorders and Therapeutic Implications, Institut Imagine, Paris, 
France.
(10)Gustave Roussy, Plateforme de Génomique, Université Paris-Saclay, UMS 
AMMICA, INSERM US23, CNRS UMS 3655, Villejuif, France.
(11)Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western 
Australia, Perth, Western Australia, Australia.
(12)Institut de Génétique Moléculaire de Montpellier (IGMM), University of 
Montpellier, CNRS, Montpellier, France.

Comment in
    J Clin Invest. 2022 Jul 15;132(14):e161659. doi: 10.1172/JCI161659.

Acute megakaryoblastic leukemia of Down syndrome (DS-AMKL) is a model of clonal 
evolution from a preleukemic transient myeloproliferative disorder requiring 
both a trisomy 21 (T21) and a GATA1s mutation to a leukemia driven by additional 
driver mutations. We modeled the megakaryocyte differentiation defect through 
stepwise gene editing of GATA1s, SMC3+/-, and MPLW515K, providing 20 different 
T21 or disomy 21 (D21) induced pluripotent stem cell (iPSC) clones. GATA1s 
profoundly reshaped iPSC-derived hematopoietic architecture with gradual 
myeloid-to-megakaryocyte shift and megakaryocyte differentiation alteration upon 
addition of SMC3 and MPL mutations. Transcriptional, chromatin accessibility, 
and GATA1-binding data showed alteration of essential megakaryocyte 
differentiation genes, including NFE2 downregulation that was associated with 
loss of GATA1s binding and functionally involved in megakaryocyte 
differentiation blockage. T21 enhanced the proliferative phenotype, reproducing 
the cellular and molecular abnormalities of DS-AMKL. Our study provides an array 
of human cell-based models revealing individual contributions of different 
mutations to DS-AMKL differentiation blockage, a major determinant of leukemic 
progression.

DOI: 10.1172/JCI156290
PMCID: PMC9282925
PMID: 35587378 [Indexed for MEDLINE]